NASDAQ: PGNY · Industrial Applications and Services · 9 alerts · CIK 1551306
Share price
$37.15Close, Nov 16
Market cap
$2.74B
Shares outstanding
73.65MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Services-Misc Health & Allied Services, NECSIC 8090
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Progyny, Inc. filings on SEC EDGAR ↗
Progyny Chief Product Officer Geoffrey Clapp Sells $28.2K of Stock
Geoffrey Clapp, Chief Product Officer, sold 774 shares of Progyny, Inc. at $36.41 a share, worth $28.2K in total on Nov 11, 2026. Shares held after the trade: 58,235 (-1.3%).
Peter Anevski, CEO, sold 236,630 shares of Progyny, Inc. at $35.61 to $36.29 a share (average $35.84) in 4 transactions, worth $8.48M in total on Nov 10, 2026. Shares held after the trade: 710,972 (-2.5%).
Progyny Executive Chairman David J. Schlanger Sells $1.25M of Stock
David J. Schlanger, Executive Chairman, sold 35,392 shares of Progyny, Inc. at $35.36 a share, worth $1.25M in total on Nov 10, 2026. Shares held after the trade: 238,462 (-12.9%).
Peter Anevski, CEO, sold 173,247 shares of Progyny, Inc. at $35.09 to $35.73 a share (average $35.68) in 4 transactions, worth $6.18M in total between Nov 5, 2026 and Nov 9, 2026. Shares held after the trade: 762,468 (-4.4%).
Progyny Executive Chairman David J. Schlanger Sells $5.88M of Stock
David J. Schlanger, Executive Chairman, sold 164,608 shares of Progyny, Inc. at $35.22 to $35.73 a share (average $35.72) in 2 transactions, worth $5.88M in total between Nov 5, 2026 and Nov 9, 2026. Shares held after the trade: 238,462 (-40.3%).
Progyny CFO Mark S. Livingston Sells $64.2K of Stock
Mark S. Livingston, CFO, sold 2,139 shares of Progyny, Inc. at $30.00 a share, worth $64.2K in total on Nov 4, 2026. Shares held after the trade: 70,314 (-3.0%).
Progyny, Inc. reported its financial results for the third quarter of 2026, maintaining its status as a large accelerated filer with 73,647,334 shares of common stock outstanding as of October 31, 2026. The filing highlights risks including high client concentration in the technology industry and the potential impact of evolving laws and regulations on reproductive rights.
Progyny reported record third-quarter 2026 results with revenue increasing 9% year-over-year to $341.3 million and net income nearly doubling to $26.3 million. The company achieved its strongest selling season ever, adding 1.3 million new covered lives for 2027 while maintaining near 100% client retention.
“We're exceptionally pleased with the results of our most recent selling season, where our momentum extended even into its latest stages, yielding 1.3 million new covered lives, our most ever in a single season, and over 85 new clients.”
Pete Anevski, Chief Executive Officer of Progyny
“We achieved strong top- and bottom-line growth this quarter, reflecting that member engagement was consistent with our expectations, and we are pleased to be in a position to raise the midpoint of our full year guidance.”
Mark Livingston, Chief Financial Officer of Progyny
Progyny COO Melissa B. Cummings Sells $52.6K of Stock
Melissa B. Cummings, COO, sold 1,879 shares of Progyny, Inc. at $28.00 a share, worth $52.6K in total on Oct 14, 2026. Shares held after the trade: 66,496 (-2.7%).